Innovative Cellular Therapeutics Holdings Ltd
CIK: 0002095697
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lyell Immunopharma, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jul 27, 2026LYEL
Lyell Immunopharma, Inc.
Other(J)Direct44K shares- - Jul 27, 2026LYEL
Lyell Immunopharma, Inc.
Other(J)Direct38.5K shares- - Jul 17, 2026LYEL
Lyell Immunopharma, Inc.
Sale(S)Direct10 shares at avg. $13.70$137 - Jul 16, 2026LYEL
Lyell Immunopharma, Inc.
Sale(S)Direct10 shares at avg. $13.73$137.3 - Jun 29, 2026LYEL
Lyell Immunopharma, Inc.
Other(J)Direct76K shares- - Jun 15, 2026LYEL
Lyell Immunopharma, Inc.
Other(J)Direct66.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 27, 2026 | LYEL Lyell Immunopharma, Inc. | Other(J) | 44,000 | - | $0 | Direct |
| Jul 27, 2026 | LYEL Lyell Immunopharma, Inc. | Other(J) | 38,500 | - | $0 | Direct |
| Jul 17, 2026 | LYEL Lyell Immunopharma, Inc. | Sale(S) | 10 | $13.70 | $137 | Direct |
| Jul 16, 2026 | LYEL Lyell Immunopharma, Inc. | Sale(S) | 10 | $13.73 | $137 | Direct |
| Jun 29, 2026 | LYEL Lyell Immunopharma, Inc. | Other(J) | 76,000 | - | $0 | Direct |
| Jun 15, 2026 | LYEL Lyell Immunopharma, Inc. | Other(J) | 66,500 | - | $0 | Direct |
1-6 of 6 transactions
About Innovative Cellular Therapeutics Holdings Ltd
Innovative Cellular Therapeutics Holdings Ltd (SEC CIK 0002095697) files insider reports with the SEC as 10% Owner of Lyell Immunopharma, Inc. (LYEL).
Signal8 holds 7 ownership filings by Innovative Cellular Therapeutics Holdings Ltd (1 Form 3, 6 Form 4), filed between Jun 18, 2026 and Jul 27, 2026. Those filings report 6 transactions, from Jun 15, 2026 to Jul 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Innovative Cellular Therapeutics Holdings Ltd's filings is in GEORGE TOWN.
Recent filings by Innovative Cellular Therapeutics Holdings Ltd
- Jul 27, 2026: Other transactions of LYEL shares (2 lines, Form 4, code J).
- Jul 17, 2026: Open-market sale of LYEL shares (Form 4, code S).
- Jul 16, 2026: Open-market sale of LYEL shares (Form 4, code S).
- Jun 29, 2026: Other transaction of LYEL shares (Form 4, code J).
- Jun 15, 2026: Other transaction of LYEL shares (Form 4, code J).
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller